Neuromuscular

After the 12-month open-label period, those treated with patisiran from the phase 3 APOLLO and phase 2 open-label parent studies maintained their improvements on the modified Neuropathy Impairment Score +7.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Paul Fisher, MD, and Gerald Grant, MD, FACS.

Sharon Hesterlee, PhD, the executive vice president and chief research officer at MDA spoke to the benefits of its new partnership with DNAnexus.

Here's what is coming soon to NeurologyLive.

The executive VP and chief research officer of MDA also discussed future plans on making MOVR and its platform accessible to centers outside of the MDA network.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 13, 2020.

COVID-19 positive patients with Guillain-Barre syndrome were predominately of demyelinating subtype and appeared more severe than non-COVID-19 patients with Guillain-Barré syndrome.

The executive VP and chief research officer of MDA spoke about how the new visualization reporting platform will also allow for easy recruitment of data to be used in future clinical trials and research studies.

The professor of neurology at the NYU Langone Grossman School of Medicine outlined the confusion on whether deaths are related to COVID-19, a symptom associated, or previously unidentified underlying condition.

New recommendations were developed for the use of rituximab, eculizumab, and methotrexate, as well as updates on previous recommendations for thymectomy.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 6, 2020.

The professor of neurology at the NYU Langone Grossman School of Medicine gave her thoughts on how her recently published data on neurologic disorders in COVID-19 compare to previously reported data.

The 12-month results from the phase 2 TOPAZ clinical trial are anticipated by the second quarter of 2021, according to Scholar Rock.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 30, 2020.

In part 2 of this interview, Elias Kouchakji, MD, gives perspective on pamrevlumab’s unique pathway as a Duchenne muscular dystrophy treatment nearing the end of the clinical pipeline.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 23, 2020.

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen provides details of the phase 3 LELANTOS trial of pamrevlumab in Duchenne muscular dystrophy.

Experts in the diagnosis and treatment of Duchenne muscular dystrophy share their perspectives on the complex care of this patient population in the NeurologyLive® Insights series “Management of Duchenne Muscular Dystrophy.”

Study results suggest daxibotulinumtoxinA has the potential to reduce the frequency of cervical dystonia treatments by up to 50% annually.

Elias Kouchakji, MD, provides details of the phase 3 LELANTOS study of novel antibody pamrevlumab for the treatment of Duchenne muscular dystrophy.

Here's what is coming soon to NeurologyLive.

The use of real-time quaking-induced conversion and protein misfolding cyclic amplification assays accurately allowed researchers to differentiate synucleinopathies from nonsynucleinopathies.